Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis Publication Current State-of-the-Art and Future Advancements of Model-Based Meta-Analysis Explore how model-based meta-analysis supports dose optimization, trial design, and regulatory decisions, plus emerging roles…CertaraJuly 16, 2026
Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer’s dementia Publication Population pharmacokinetic analysis and exposure–response analysis of brexpiprazole in Japanese patients with agitation in Alzheimer’s dementia Explore how population pharmacokinetic and exposure–response modeling informed brexpiprazole dosing in Japanese patients with agitation…CertaraJuly 16, 2026
Dosimetry for radiopharmaceutical therapy: From measurement to dose justification Blog Dosimetry for radiopharmaceutical therapy: From measurement to dose justification Why dosimetry for radiopharmaceutical therapy needs more than absorbed dose. How BED, radiation dosimetry &…Hunter Stephens, PhDJuly 7, 2026
Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients Publication Population PK Modeling Supporting the Aripiprazole Two-Injection Start Regimen in Japanese Patients Learn how population PK modeling and simulation supported a regulatory strategy for a simplified aripiprazole…Danielle PillsburyJuly 7, 2026
Cracking the code on NCA: How Pinnacle 21 helps de-risk PK analyses Blog Cracking the code on NCA: How Pinnacle 21 helps de-risk PK analyses Learn how Pinnacle 21, strong data foundations, and better workflows reduce risk in PK noncompartmental…Wendy YoungJuly 7, 2026
5 Key Principles of Modern PK/PD in 2026 Guide 5 Key Principles of Modern PK/PD in 2026 Explore other Phoenix solutions to enhance your PK/PD workflow and discover how Phoenix helps you…CertaraJune 30, 2026
63 runs and no convergence: When RsNLME succeeded where other PK/PD solutions couldn’t BlogCase Study 63 runs and no convergence: When RsNLME succeeded where other PK/PD solutions couldn’t After 63 failed runs on a 16-ODE neutropenia model, RsNLME achieved PK/PD convergence on the…Stephen DuffullJune 23, 2026
Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling Poster Machine Learning-Based Covariate Selection for Population Pharmacokinetic Modeling Authors: Ibtissem Rebai (Certara), Stephen Duffull (Certara), Ayman Akil (Certara), Anna Largajolli (Certara), Floris Fauchet…CertaraJune 22, 2026
Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices Poster Shaping the future of AI/ML in pharmacometrics through collaboration, education and best practices Discover how the AI/ML Special Interest Group is advancing responsible artificial intelligence in pharmacometrics through…CertaraJune 22, 2026
Model Smarter, Not Harder: Introducing Model Designer On-Demand Webinar Model Smarter, Not Harder: Introducing Model Designer Watch Model Designer on demand: Certara's browser based tool for faster NLME model discovery, configuration,…CertaraJune 10, 2026